Lincoln National Corp increased its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 7.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The company owned 42,894 shares of the biopharmaceutical company after buying an additional 3,052 shares during the quarter. Lincoln National Corp’s shares in Bristol-Myers Squibb were worth $2,326,000, according to its most recent filing with the Securities and Exchange Commission.

Other hedge funds and institutional investors have also recently added to or reduced their stakes in the company. Westside Investment Management Inc. increased its stake in shares of Bristol-Myers Squibb by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 204 shares in the last quarter. Traynor Capital Management Inc. increased its position in Bristol-Myers Squibb by 2.8% in the first quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 207 shares in the last quarter. Fulton Breakefield Broenniman LLC increased its stake in Bristol-Myers Squibb by 4.6% in the fourth quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 209 shares in the last quarter. Chapin Davis Inc. increased its position in shares of Bristol-Myers Squibb by 1.2% in the 4th quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock worth $943,000 after acquiring an additional 214 shares during the period. Finally, Accurate Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 4.0% in the 1st quarter. Accurate Wealth Management LLC now owns 5,612 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 216 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street analysts predict growth

A number of research firms have recently commented on BMY. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. Barclays lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the stock in a research report on Friday, April 26th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $60.00.

View our latest research report on Bristol-Myers Squibb

Bristol-Myers Squibb Price Development

Shares of NYSE BMY opened at $40.00 on Tuesday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $65.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a 50-day moving average price of $42.17 and a 200-day moving average price of $47.65.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings results on Thursday, April 25. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. In the year-ago period, the company posted earnings per share of $2.05. The company’s quarterly revenue increased 4.7% compared to the year-ago quarter. On average, equities research analysts expect Bristol-Myers Squibb to post 0.58 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will receive a dividend of $0.60. The ex-dividend date is Friday, July 5th. This represents an annualized dividend of $2.40 and a dividend yield of 6.00%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, sells and sells biopharmaceutical products worldwide. Its products are used in hematology, oncology, cardiovascular, immunology, fibrotics and neuroscience diseases. The Company’s products include Eliquis for reduction of the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, gastric and esophageal cancers; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome positive chronic myeloid leukemia.

Featured Stories

Want to know which other hedge funds own BMY? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.